Rollo Capital Management ("RCM") is a Boston-based investment firm established in January 2008 and focused on industrial sectors, with an emphasis on materials, capital goods, chemicals, technology, automotive, energy and aerospace. RCM is the manager and advisor of CIP (Change in Progress), LP, an investment partnership pursuing medium and long-term investment strategies in publicly-listed industrial companies with an emphasis on change and innovation and with a value-based philosophy. RCM is also the manager of RCV I, LLC, an investment vehicle focused on early-stage innovative companies in the areas of materials and automation. Portfolio investments include: Gelesis (NYSE: GLS), enEvolv (acquired by Zymergen; NYSE: ZY), Continuus Pharmaceuticals (www.continuuspharma.com), PanTher Therapeutics (www.panthertx.com), Pearl Bio (pearlbio.com).
